Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Whole-body ultra-low dose CT using spectral shaping for detection of osteolytic lesion in multiple myeloma.

Suntharalingam S, Mikat C, Wetter A, Guberina N, Salem A, Heil P, Forsting M, Nassenstein K.

Eur Radiol. 2018 Jan 10. doi: 10.1007/s00330-017-5243-8. [Epub ahead of print]

PMID:
29322333
2.

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.

Freise KJ, Hu B, Salem AH.

Eur J Clin Pharmacol. 2018 Jan 4. doi: 10.1007/s00228-017-2403-3. [Epub ahead of print]

PMID:
29302721
3.

Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium.

Krasnick BA, Jin LX, Davidson JT 4th, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, Martin RCG, Isom CA, Scoggins C, Schmidt CR, Shen P, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC.

J Surg Oncol. 2017 Dec 28. doi: 10.1002/jso.24836. [Epub ahead of print]

PMID:
29284072
4.

The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study.

Khella MS, Salem AM, Abdel-Rahman O, Saad AS.

Genet Test Mol Biomarkers. 2017 Dec 20. doi: 10.1089/gtmb.2017.0146. [Epub ahead of print]

PMID:
29260910
5.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

PMID:
29246803
6.

Magnetic resonance imaging in precision radiation therapy for lung cancer.

Bainbridge H, Salem A, Tijssen RHN, Dubec M, Wetscherek A, Van Es C, Belderbos J, Faivre-Finn C, McDonald F; lung tumour site group of the international Atlantic MR-Linac Consortium.

Transl Lung Cancer Res. 2017 Dec;6(6):689-707. doi: 10.21037/tlcr.2017.09.02. Review.

7.

Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival.

Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Weiss M, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM.

J Surg Oncol. 2017 Dec 4. doi: 10.1002/jso.24945. [Epub ahead of print]

PMID:
29205351
8.

Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis.

Thumallapally N, Meshref A, Mousa M, Hendawi M, Lan M, Salem AI, Forte F.

J Gastrointest Oncol. 2017 Oct;8(5):825-832. doi: 10.21037/jgo.2017.06.19.

9.

Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium.

Schimizzi GV, Jin LX, Davidson JT 4th, Krasnick BA, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Weber SM, Salem A, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Martin RCG, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC.

HPB (Oxford). 2017 Nov 20. pii: S1365-182X(17)31090-0. doi: 10.1016/j.hpb.2017.10.003. [Epub ahead of print]

PMID:
29169904
10.

A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.

Poorman CE, Ethun CG, Postlewait LM, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solórzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK.

Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.

PMID:
29164414
11.

Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.

Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK.

Ann Surg. 2017 Oct 23. doi: 10.1097/SLA.0000000000002574. [Epub ahead of print]

PMID:
29064885
12.

Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.

Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK.

Clin Pharmacol Drug Dev. 2017 Oct 23. doi: 10.1002/cpdd.395. [Epub ahead of print]

PMID:
29058801
13.

Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.

Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH.

Xenobiotica. 2017 Oct 13:1-6. doi: 10.1080/00498254.2017.1381779. [Epub ahead of print]

PMID:
29027832
14.

The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium.

O'Connor SC, Mogal H, Russell G, Ethun C, Fields RC, Jin L, Hatzaras I, Vitiello G, Idrees K, Isom CA, Martin R, Scoggins C, Pawlik TM, Schmidt C, Poultsides G, Tran TB, Weber S, Salem A, Maithel S, Shen P.

J Gastrointest Surg. 2017 Dec;21(12):2016-2024. doi: 10.1007/s11605-017-3537-4. Epub 2017 Oct 4.

PMID:
28986752
15.

Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.

Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O'Connor JPB, Faivre-Finn C.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx160. Review.

PMID:
28922791
16.

Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies.

Buettner S, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Weiss M, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Koerkamp BG, Maithel SK, Pawlik TM.

J Gastrointest Surg. 2017 Nov;21(11):1813-1820. doi: 10.1007/s11605-017-3571-2. Epub 2017 Sep 14.

PMID:
28913712
17.

Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium.

Beal EW, Lyon E, Kearney J, Wei L, Ethun CG, Black SM, Dillhoff M, Salem A, Weber SM, Tran TB, Poultsides G, Shenoy R, Hatzaras I, Krasnick B, Fields RC, Buttner S, Scoggins CR, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Pawlik TM, Schmidt CR.

HPB (Oxford). 2017 Dec;19(12):1104-1111. doi: 10.1016/j.hpb.2017.08.009. Epub 2017 Sep 7.

PMID:
28890310
18.

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.

Geara FB, Bulbul M, Khauli RB, Andraos TY, Abboud M, Al Mousa A, Sarhan N, Salem A, Ghatasheh H, Alnsour A, Ayoub Z, Gheida IA, Charafeddine M, Shahait M, Shamseddine A, Gheida RA, Khader J.

Radiat Oncol. 2017 Sep 7;12(1):149. doi: 10.1186/s13014-017-0884-y.

19.

A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth.

Chander Roland B, Mullin GE, Passi M, Zheng X, Salem A, Yolken R, Pasricha PJ.

Dig Dis Sci. 2017 Dec;62(12):3525-3535. doi: 10.1007/s10620-017-4726-4. Epub 2017 Sep 4.

PMID:
28871499
20.

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.

Li M, Dave N, Salem AH, Freise KJ.

Medicine (Baltimore). 2017 Sep;96(35):e7988. doi: 10.1097/MD.0000000000007988. Review.

Supplemental Content

Loading ...
Support Center